0 Articles
0 News
0 Properties
0 Page
0 Blog

News

FDB Announces $300M Brazos Valley Facility

The following is an announcement from the Office of the Governor of Texas:
 
AUSTIN – Governor Greg Abbott today announced that FUJIFILM Diosynth Biotechnologies will expand their campus in College Station-Bryan with an additional commercial manufacturing facility. FUJIFILM Diosynth Biotechnologies, a partnership between FUJIFILM Corporation and Mitsubishi Corporation, is a world-leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and viral gene therapies. The project is expected to create approximately 150 new jobs and approximately $300 million in capital investment from FUJIFILM Corporation. A Texas Enterprise Fund (TEF) grant of $1,500,000 has been extended to FUJIFILM Diosynth Biotechnologies.
 
"FUJIFILM Diosynth Biotechnologies' expansion is wonderful news for the hardworking people of College Station-Bryan, and it will bring more opportunities for Texans to develop life-saving technology and treatment," said Governor Abbott. "The biotechnology industry is growing at a tremendous rate in Texas, and I thank FUJIFILM Diosynth Biotechnologies for their continued investment in the Brazos Valley that will keep the Lone Star State competitive in this field."
 
"The biopharmaceutical industry’s need for manufacturing capacity continues to grow rapidly," said Gerry Farrell, chief operating officer for FUJIFILM Diosynth Biotechnologies Texas. "Committed to being a partner for life for our customers, we will continue to invest in the right technology and talent to support our partners in bringing to market these life-impacting medicines. We are grateful to Governor Greg Abbott, and the State of Texas for its commitment to supporting the growth of the Texas biocorridor, and creating highly-skilled jobs in the state."
 
"We’re incredibly excited about the expansion of the FUJIFILM Diosynth Biotechnologies for the Brazos Valley," said State Senator Charles Schwertner. "As a pharmacist and physician, I understand the importance of encouraging our state’s growing biopharmaceutical industry. The Brazos Valley is an ideal setting for this kind of expansion due to its business-friendly environment and the ability to recruit world class scientific minds from Texas A&M University. The opportunity and economic growth brought on by today’s announcement will help Brazos County remain one of the best places in America to live, work, and raise a family."
 
"With FUJIFILM Diosynth Biotechnologies’ new state-of-the art facility, our community will play a significant role in meeting market demands of life saving solutions," said State Representative John Raney. "FUJIFILM and Governor Abbott's investment and commitment to our community is invaluable and appreciated beyond measure.”
 
"The City of College Station is thankful that it can proudly point to FUJIFILM Diosynth Biotechnologies as a vibrant and cutting-edge partner in our community,” said College Station Mayor Karl Mooney. "Since its arrival in 2014, FUJIFILM Diosynth Biotechnologies has been a trusted partner with College Station and the entire Brazos Valley. This new addition to the company’s already impressive operations here will make a positive impact on our community for years to come."
 
"The Bryan-College Station community welcomes and appreciates FUJIFILM Diosynth Biotechnologies’ upcoming investments and additional job creation at its Brazos Valley biocorridor campus,” said Bryan Mayor Andrew Nelson. "These new employees will forge great biopharmaceutical innovations in a community dedicated to creating an outstanding atmosphere for them and their families, both professionally and personally. On behalf of the City of Bryan, my thanks to FUJIFILM Diosynth Biotechnologies for its continued commitment to our region."
 
"Brazos County continues to prove itself to be a prime location for companies in the bio industry, and FUJIFILM Diosynth Biotechnologies continues to be a leader in our bio and overall business ecosystems," said Brazos County Judge Duane Peters. "We appreciate this new investment at the company’s biocorridor campus and the jobs coming with it."
 
"FUJIFILM Diosynth Biotechnologies makes a global impact every day from the Brazos Valley," said Brazos Valley Economic Development Corporation's President and CEO Matt Prochaska. "We are honored that this worldwide industry leader from Japan continues to see our Texas community’s talent, resources, institutions and quality of life as advantageous for their goals and growth. The Brazos Valley is better because we are partners."
 
View more information about FUJIFILM Diosynth Biotechnologies.
 

 
Leadership of The Texas A&M University System and Texas A&M University offered their reactions to the announcement by the Governor:
 
“Once again, the partnership begun in 2014 between FUJIFILM Diosynth Biotechnologies and The Texas A&M University System is paying dividends. I applaud Governor Abbott for using the Texas Enterprise Fund to close this deal. I congratulate FDB for again making a significant economic investment in its facilities here. FDB is helping Bryan-College Station become a national hub for bio-manufacturing and product development.” - John Sharp, Texas A&M University System Chancellor
 
“FUJIFILM Diosynth Biotechnologies has become a major local employer since it arrived in College Station seven years ago, hiring many Aggie graduates. These types of jobs, economic investments and medical product developments will benefit our community, state and nation for generations.” - M. Katherine Banks, Texas A&M University President
 

 
The following is a press release from FUJIFILM Diosynth Biotechnologies put out following the Governor's announcement:
 
COLLEGE STATION, Texas, December 14, 2021― FUJIFILM Diosynth Biotechnologies,  a world-leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and viral gene therapies, today announced an expansion of its single-use manufacturing campus in College Station through the addition of a new cGMP production facility that will double the Company’s advanced therapy and vaccine manufacturing capacity in the U.S. This investment is supported by a $1.5 million Texas Enterprise Fund Award to support the creation of approximately 150 skilled positions including manufacturing and operations by 2024.
 
The investment of approximately $300 million for facility construction is part of a previously announced $850 million global capital investment package initially outlined by FUJIFILM Corporation in June 2021. The investment will further expand FUJIFILM Diosynth Biotechnologies’ manufacturing capabilities to better support its current and future partners in advancing their life-impacting products.
 
This new facility, expected to be operational by 2024, will add approximately 138,000 sq.ftto the existing campus growing the site to 300,000 sq. ft2. The new site will house multiple 500L and 2,000L bioreactors and associated purification equipment deploying single-use technology.
 
“FUJIFILM Diosynth Biotechnologies’ expansion is wonderful news for the hardworking people of College Station-Bryan, and it will bring more opportunities for Texans to develop life-saving technology and treatment,” said Governor Greg Abbott. “The biotechnology industry is growing at a tremendous rate in Texas, and I thank FUJIFILM Diosynth Biotechnologies for their continued investment in the Brazos Valley that will keep the Lone Star State competitive in this field.”
 
“As a leader in the advanced therapy market, this complements FUJIFILM Diosynth Biotechnologies’ existing global footprint which now include sites in Watertown, Massachusetts, USA and Darlington, United Kingdom,” said Martin Meeson, chief executive officer, FUJIFILM Diosynth Biotechnologies.
 
“As the need for advanced therapies development and manufacturing capacity grows, we will continue to invest in the right technology and talent to support our partners in bringing to market these life-impacting medicines,” said Gerry Farrell, chief operating officer, FUJIFILM Diosynth Biotechnologies, Texas. “We are grateful to Governor Greg Abbott, and the State of Texas for its commitment to supporting the growth of the Texas biocorridor, and creating highly-skilled jobs in the state. We are also grateful to the cities of Bryan and College Station and Brazos County for their continued support with this initiative.”
 
The Texas Enterprise Fund awards support the creation of quality jobs and leverage  private investment for business activities designed to strengthen the economic future of the state.
 
About FUJIFILM Diosynth Biotechnologies
FUJIFILM Diosynth Biotechnologies is an industry-leading Biologics Contract Development and Manufacturing Organization (CDMO) with locations in Teesside, UK, RTP, North Carolina, College Station, Texas and Hillerød, Denmark. FUJIFILM Diosynth Biotechnologies has over thirty years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway™ microbial and Apollo™X cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. FUJIFILM Diosynth Biotechnologies is a partnership between FUJIFILM Corporation and Mitsubishi Corporation.  For more information, go to: www.fujifilmdiosynth.com.
 
About Fujifilm
FUJIFILM Corporation is an operating company of FUJIFILM Holdings Corporation. FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, highly functional materials, document solutions and imaging products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2021, the company had global revenues of $21 billion, at an exchange rate of 106 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit: https://www.fujifilmholdings.com.
 
 
 
 

Media Coverage